Marc C. Smaldone

Marc C. Smaldone

Auto-generated profile, based on publicly available information

Marc C. Smaldone

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2014 in Cancer
Verified
Journal Article
Open access
PDF file
JMJeffrey M. Martin
Jeffrey M. Martin
EHElizabeth A. Handorf
Elizabeth A. Handorf
AKAlexander Kutikov
Alexander Kutikov
RURobert G. Uzzo
Robert G. Uzzo
JBJustin E. Bekelman
Justin E. Bekelman
MSMarc C. Smaldone
Marc C. Smaldone
BACKGROUND: Brachytherapy has been shown to be an efficacious and cost‐effective treatment among patients with localized prostate cancer. In this study, the authors examined trends in brachytherapy use for localized prostate cancer using a large national cancer registry.METHODS: In the National Cancer Data Base (NCDB), a total of 1,547,941 patients with localized prostate cancer were identified from 1998 through 2010. Excluding patients with lymph node‐positive or metastatic disease, the authors examined primary treatment trends focusing on the use of brachytherapy over time. Patients with available data (2004‐2009) were stratified by National Comprehensive Cancer Network risk criteria. Controlling for year of diagnosis and demographic, clinical, and pathologic characteristics, multivariate analyses were performed examining the association between patient characteristics and receipt of brachytherapy.RESULTS: In the study cohort, brachytherapy use reached a peak of 16.7% in 2002, and then steadily declined to a low of 8% in 2010. Of the 719,789 patients with available data for risk stratification, 41.1%, 35.3%, and 23.6%, respectively, met low, intermediate, and high National Comprehensive Cancer Network risk criteria. After adjustment, patients of increasing age and those with Medicare insurance were more likely to receive brachytherapy. In contrast, patients with intermediate‐risk or high‐risk disease, Medicaid insurance, increasing comorbidity count, and increasing year of diagnosis were less likely to receive brachytherapy.CONCLUSIONS: For patients with localized prostate cancer who are treated at National Cancer Data Base institutions, there has been a steady decline in brachytherapy use since 2003. For low‐risk patients, the declining use of brachytherapy monotherapy compared with more costly emerging therapies has significant health policy implications. Cancer 2014;120:2114–2121. © 2014 American Cancer Society.

1 November 2014 in European Urology
Verified
Journal Article
Closed access
AMAndrea Minervini
Andrea Minervini
MCMarco Carini
Marco Carini
RURobert G. Uzzo
Robert G. Uzzo
RCRiccardo Campi
Riccardo Campi
MSMarc C. Smaldone
Marc C. Smaldone
AKAlexander Kutikov
Alexander Kutikov

1 April 2017 in Medical Care
Verified
Journal Article
Closed access
MSMarc C. Smaldone
Marc C. Smaldone
BEBrian Lee Egleston
Brian Lee Egleston
JHJohn M. Hollingsworth
John M. Hollingsworth
BHBrent K. Hollenbeck
Brent K. Hollenbeck
DMDavid C. Miller
David C. Miller
AKAlexander Kutikov
Alexander Kutikov
Background and Objectives: The paradoxical rise in overall and cancer-specific mortality despite increased detection and treatment of renal cell carcinoma (RCC) is termed “treatment disconnect.” We reassess this phenomenon by evaluating impact of missing data and rising incidence on mortality trends. Research Design, Subjects, and Measures: Using Surveillance, Epidemiology, and End Results data, we identified patients with RCC diagnosis from 1973 to 2011. We estimated mortality rates by tumor size after accounting for lags from diagnosis to death using multiple imputations for missing data from 1983. Mortality rates were estimated irrespective of tumor size after adjustment for prior cumulative incidence using ridge regression. Results: A total of 78,891 patients met inclusion criteria. Of 70,212 patients diagnosed since 1983, 10.4% had missing data. Significant attenuation in cancer-specific mortality was noted from 1983 to 2011 when comparing observed with imputed rates: Δobs0.05 versus Δimp0.10 (P=0.001, <2 cm tumors); Δobs0.29 versus Δimp0.18 (P=0.005, 2–4 cm tumors); Δobs0.46 versus Δimp–0.20 (P<0.001, 4–7 cm tumors); Δobs0.93 versus Δimp–0.15 (P7 cm tumors). Holding incidence of RCC constant to 2011 rates, temporal increase in overall mortality for all patients was attenuated (P<0.001) when comparing observed estimates (3.9–6.8) with 2011 adjusted estimates (5.9–7.1), suggesting that rapidly rising incidence may influence reported overall mortality trends. These findings were supported by assessment of mortality to incidence ratio trends. Conclusions: Missing data and rising incidence may contribute substantially to the “treatment disconnect” phenomenon when examining mortality rates in RCC using tumor registry data. Caution is advised when basing clinical and policy decisions on these data.

12 September 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
BRBenjamin T Ristau
Benjamin T Ristau
EHElizabeth A. Handorf
Elizabeth A. Handorf
DCDavid B. Cahn
David B. Cahn
AKAlexander Kutikov
Alexander Kutikov
RURobert G. Uzzo
Robert G. Uzzo
MSMarc C. Smaldone
Marc C. Smaldone

9 April 2013 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MSMarc C. Smaldone
Marc C. Smaldone
ACAnthony T. Corcoran
Anthony T. Corcoran
RURobert G. Uzzo
Robert G. Uzzo

1 November 2014 in Journal of Urology
Verified
Journal Article
Closed access
JTJeffrey J. Tomaszewski
Jeffrey J. Tomaszewski
EHElizabeth Handorf
Elizabeth Handorf
ACAnthony T. Corcoran
Anthony T. Corcoran
YWYu-Ning Wong
Yu-Ning Wong
RMReza Mehrazin
Reza Mehrazin
MSMarc C. Smaldone
Marc C. Smaldone
Hypothesizing that changing hospitals between diagnosis and definitive therapy (care transition) may delay timely treatment, we identified the association between care transitions and a treatment delay of 3 months or greater in patients with muscle invasive bladder cancer. Using the National Cancer Database we identified all patients with stage II or greater urothelial carcinoma treated from 2003 to 2010. Care transition was defined as a change in hospital from diagnosis to definitive treatment course, that is diagnosis to radical cystectomy or the start of neoadjuvant chemotherapy. Logistic regression models were used to test the association between care transition and treatment delay. Of 22,251 patients 14.2% experienced a treatment delay of 3 months or greater and this proportion increased with time (13.5% in 2003 to 2006 vs 14.8% in 2007 to 2010, p = 0.01). Of patients who underwent a care transition 19.4% experienced a delay to definitive treatment compared to 10.7% diagnosed and treated at the same hospital (p <0.001). The proportion of patients with a care transition increased during the study period (37.4% in 2003 to 2006 vs 42.3% in 2007 to 2010, p <0.001). After adjustment patients were more likely to experience a treatment delay when undergoing a care transition (OR 2.0, 95% CI 1.8-2.2). Patients with muscle invasive bladder cancer who underwent a care transition were more likely to experience a treatment delay of 3 months or greater. Strategies to expedite care transitions at the time of hospital referral may improve quality of care.